SCN9A and ovarian cancer: Our bioinformatic analysis suggested a potential association between VGSC expression and the immune subtypes in certain cancer types (Table 4 column 10), hinting at the possibility of using VGSCs as a prediction biomarker or enhancer in cancer immunotherapy, such as Nav1.5 in colon, breast, and ovarian cancer and Nav1.7 in breast, prostate, lung, and gastric cancer.